Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis

ConclusionTreatment with guselkumab provided robust and sustained benefits across multiple PsA domains through 1  year, indicating that guselkumab is an effective therapy for the diverse manifestations of PsA.Trial registrationNCT03162796; NCT03158285
Source: Rheumatology - Category: Rheumatology Source Type: research